<?xml version='1.0' encoding='UTF-8'?>
<DOC><DOCNO> FR89209-0065 </DOCNO><DOCID>fr.2-09-89.f2.A1064</DOCID><TEXT><ITAG tagnum="94"><ITAG tagnum="69"><ITAG tagnum="50"> DEPARTMENT OF HEALTH AND HUMAN SERVICES</ITAG><ITAG tagnum="18">Food and Drug Administration</ITAG><ITAG tagnum="41">[Docket No. 88M-0399]</ITAG><ITAG tagnum="56">Abbott Laboratories; Premarket Approval of Murine<T2/> Sterile Saline Solution</ITAG><ITAG tagnum="10"><T2>AGENCY:</T2> Food and Drug Administration.</ITAG><ITAG tagnum="10"><T2>ACTION:</T2> Notice.</ITAG><ITAG tagnum="10"><T2>SUMMARY:</T2> The Food and Drug Administration (FDA) is announcingits approval of the application by Abbott Laboratories, Columbus, OH, forpremarket approval, under the Medical Device Amendments of 1976, of MurineSterile Saline Solution. The device is to be manufactured under an agreementwith Paco Pharmaceutical Services, Inc., Lakewood, NJ, which has authorizedAbbott Laboratories to incorporate information contained in its approvedpremarket approval application for the Charter Labs Nonpreserved SalineSolution. FDA's Center for Devices and Radiological Health (CDRH) notifiedthe applicant, by letter of November 8, 1988, of the approval of the application.</ITAG><ITAG tagnum="10"><T2>DATE:</T2> Petitions for administrative review by March 13, 1989.</ITAG><ITAG tagnum="10"><T2>ADDRESS:</T2> Written requests for copies of the summary of safetyand effectiveness data and petitions for administrative review to the DocketsManagement Branch (HFA-305), Food and Drug Administration, Rm. 4-62, 5600Fishers Lane, Rockville, MD 20857.</ITAG><ITAG tagnum="10"><T2>FOR FURTHER INFORMATION CONTACT:</T2> David M. Whipple, Center forDevices and Radiological Health (HFZ-460), Food and Drug Administration,8757 Georgia Ave., Silver Spring, MD 20910, 301-427-7940.</ITAG><ITAG tagnum="10"><T2>SUPPLEMENTARY INFORMATION:</T2> On July 28, 1988, Abbott Laboratories,Columbus, OH 43215, submitted to CDRH an application for premarket approvalof Murine Sterile Saline Solution. The device is indicated for use inthe rinsing, heat disinfection, and storage of soft (hydrophilic) contactlenses. The application includes authorization from Paco PharmaceuticalServices, Inc., Lakewood, NJ 08701, to incorporate information containedin its approved premarket approval application for the Charter Labs Non-preservedSaline Solution. On November 8, 1988, CDRH approved the application by a letter to theapplicant from the Acting Director of the Office of Device Evaluation,CDRH. A summary of the safety and effectiveness data on which CDRH based itsapproval is on file in the Dockets Management Branch (address above) andis available from that office upon written request. Requests should beidentified with the name of the device and the docket number found in bracketsin the heading of this document. A copy of all approved labeling is available for public inspection atCDRH_contact David M. Whipple (HFZ-460), address above.<ITAG tagnum="84"> Opportunity for Administrative Review</ITAG> Section 5l5(d)(3) of the Federal Food, Drug, and Cosmetic Act (the act)(21 U.S.C. 360e(d)(3)) authorizes any interested person to petition, undersection 515(g) of the act (21 U.S.C. 360e(g)), for administrative reviewof CDRH's decision to approve this application. A petitioner may requesteither a formal hearing under Part 12 (21 CFR Part 12) of FDA's administrativepractices and procedures regulations or a review of the application andCDRH's action by an independent advisory committee of experts. A petitionis to be in the form of a petition for reconsideration under andSection;10.33(b) (21 CFR 10.33(b)). A petitioner shall identify the form of reviewrequested (hearing or independent advisory committee) and shall submitwith the petition supporting data and information showing that there isa genuine and substantial issue of material fact for resolution throughadministrative review. After reviewing the petition, FDA will decide whetherto grant or deny the petition and will publish a notice of its decisionin the <T4> Federal Register</T4>. If FDA grants the petition, the notice willstate the issue to be reviewed, the form of review to be used, the personswho may participate in the review, the time and place where the reviewwill occur, and other details. Petitioners may, at any time on or before March 13, 1989, file with theDockets Management Branch (address above) two copies of each petition andsupporting data and information, identified with the name of the deviceand the docket number found in brackets in the heading of this document.Received petitions may be seen in the office above between 9 a.m. and 4p.m., Monday through Friday. This notice is issued under the Federal Food, Drug, and Cosmetic Act (secs.515(d), 520(h), 90 Stat. 554-555, 571 (21 U.S.C. 360e(d), 360j(h))) andunder authority delegated to the Commissioner of Food and Drugs (21 CFR5.10) and redelegated to the Director, Center for Devices and RadiologicalHealth (21 CFR 5.53).<ITAG tagnum="21"> Dated: February 1, 1989.</ITAG><ITAG tagnum="6"> Walter E. Gundaker,</ITAG><ITAG tagnum="4"> Acting Deputy Director, Center for Devices and Radiological Health.</ITAG><ITAG tagnum="40">[FR Doc. 89-3055 Filed 2-8-89; 8:45 am]</ITAG><ITAG tagnum="68">BILLING CODE 4160-01-M</ITAG></ITAG></ITAG></ITAG></TEXT></DOC>